SCHEMBL3594347

SCHEMBL3594347

CCOc1ccc(CCN2CCC(N(C)C(=O)O)CC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 10/20 0.58
CCR5 P51681 2/20 0.54
DRD3 P35462 2/20 0.52
SLC22A1 O15245 1/20 0.52
NR1I2 O75469 1/20 0.52
ABCB1 P08183 1/20 0.52
CHRM1 P11229 1/20 0.52
DRD2 P14416 1/20 0.52
ADRA2B P18089 1/20 0.52
ADRA2C P18825 1/20 0.52
CHRM3 P20309 1/20 0.52
MAOA P21397 1/20 0.52
DRD4 P21917 1/20 0.52
MAOB P27338 1/20 0.52
ADRA1A P35348 1/20 0.52
HRH1 P35367 1/20 0.52
ADRA1B P35368 1/20 0.52
OPRD1 P41143 1/20 0.52
OPRK1 P41145 1/20 0.52
CHRNA4 P43681 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3598407 0.83 OPRM1 (0.53) OPRM1DRD3SLC22A1NR1I2ABCB1
SCHEMBL3604727 0.81 C5AR1 (0.60) OPRM1CCR5DRD2SIGMAR1KMT2A
SCHEMBL4545375 0.79 OPRM1 (0.81) OPRM1DRD3SLC22A1NR1I2ABCB1
SCHEMBL3938953 0.79 CCR4 (0.58) OPRM1DRD3SLC22A1NR1I2ABCB1
SCHEMBL3594346 0.78 LTA4H (0.55) OPRM1DRD3KMT2A
SCHEMBL3592179 0.77 SIGMAR1 (0.61) DRD3DRD2SIGMAR1MEN1KMT2A
SCHEMBL3938283 0.76 CHRM4 (0.52) OPRM1DRD3DRD2ADRA1AHRH1
SCHEMBL19658495 0.76 CCR5 (0.58) OPRM1CCR5DRD3SLC22A1NR1I2
SCHEMBL2981930 0.76 DRD3 (0.46) OPRM1DRD3KCNH2SIGMAR1KMT2A
SCHEMBL5709497 0.75 DRD3 (0.48) OPRM1DRD3DRD2CHRM3ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720550-B1 DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS SANOFI AVENTIS (FR) 2009-04-15 EP claimed
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2010-11-04 US disclosed
EP-1720550-B1 DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS SANOFI AVENTIS (FR) 2009-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 OPRM1 782/4885CCR5 1522/4885DRD3 1682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.